Allergan and Zeltiq announce expiration of Hart-Scott-Rodino waiting period for pending transaction.
Allergan plc, a global biopharmaceutical company, and Zeltiq Aesthetics, Inc., a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, announced Thursday that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the HSR Act) has expired with respect to Allergan’s proposed acquisition of Zeltiq.
On February 13, 2017, Allergan and Zeltiq entered into a definitive agreement under which Allergan has agreed to acquire Zeltiq. Following the announcement of the transaction, each of Allergan and Zeltiq filed a Notification and Report Form pursuant to the HSR Act with the Antitrust Division of the U.S. Department of Justice and the Federal Trade Commission.
Expiration of the waiting period under the HSR Act satisfies one of the conditions to the closing of the pending acquisition, which remains subject to other customary closing conditions, including approval by the stockholders of Zeltiq.
Zeltiq is scheduled to hold a stockholder meeting on April 27, 2017 to vote on the proposed transaction, and the companies expect the transaction to be completed shortly thereafter.
(Source: Allergan plc)
